FDA Guidance for Industry: Postapproval Changes to Drug Substances

Titel:
FDA Guidance for Industry: Postapproval Changes to Drug Substances
Herkunft/Verlag:

FDA

Inhalt:
This guidance provides recommendations to holders of approved new drug applications (NDAs), abbreviated new drug applications (ANDAs), new animal drug applications (NADAs), and abbreviated new animal drug applications (ANADAs) and holders of drug master files (DMFs) and veterinary master files (VMFs) who want to make a change to the drug substance manufacturing process during the drug product application’s postapproval period.

Zurück

GMP Seminare nach Thema